• Media type: E-Article
  • Title: Evolution of HIV-1 envelope towards reduced neutralization sensitivity, as demonstrated by contemporary HIV-1 subtype B from the United States
  • Contributor: Wieczorek, Lindsay; Sanders-Buell, Eric; Zemil, Michelle; Lewitus, Eric; Kavusak, Erin; Heller, Jonah; Molnar, Sebastian; Rao, Mekhala; Smith, Gabriel; Bose, Meera; Nguyen, Amy; Dhungana, Adwitiya; Okada, Katherine; Parisi, Kelly; Silas, Daniel; Slike, Bonnie; Ganesan, Anuradha; Okulicz, Jason; Lalani, Tahaniyat; Agan, Brian K.; Crowell, Trevor A.; Darden, Janice; Rolland, Morgane; Vasan, Sandhya; [...]
  • imprint: Public Library of Science (PLoS), 2023
  • Published in: PLOS Pathogens
  • Language: English
  • DOI: 10.1371/journal.ppat.1011780
  • ISSN: 1553-7374
  • Keywords: Virology ; Genetics ; Molecular Biology ; Immunology ; Microbiology ; Parasitology
  • Origination:
  • Footnote:
  • Description: <jats:p>Subtype B HIV-1 has been the primary driver of the HIV-1 epidemic in the United States (U.S.) for over forty years and is also a prominent subtype in the Americas, Europe, Australia, the Middle East and North Africa. In this study, the neutralization profiles of contemporary subtype B Envs from the U.S. were assessed to characterize changes in neutralization sensitivities over time. We generated a panel of 30 contemporary pseudoviruses (PSVs) and demonstrated continued diversification of subtype B Env from the 1980s up to 2018. Neutralization sensitivities of the contemporary subtype B PSVs were characterized using 31 neutralizing antibodies (NAbs) and were compared with strains from earlier in the HIV-1 pandemic. A significant reduction in Env neutralization sensitivity was observed for 27 out of 31 NAbs for the contemporary as compared to earlier-decade subtype B PSVs. A decline in neutralization sensitivity was observed across all Env domains; the NAbs that were most potent early in the pandemic suffered the greatest decline in potency over time. A meta-analysis demonstrated this trend across multiple subtypes. As HIV-1 Env diversification continues, changes in Env antigenicity and neutralization sensitivity should continue to be evaluated to inform the development of improved vaccine and antibody products to prevent and treat HIV-1.</jats:p>
  • Access State: Open Access